SCHEMBL17078239

SCHEMBL17078239

O=C(Oc1nsnc1N1CCCCC1)N1CCCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LIPA P38571 8/20 1.00
ALDH1A1 P00352 5/20 0.49
MAPT P10636 3/20 0.49
HSD17B10 Q99714 3/20 0.49
KDM4E B2RXH2 1/20 0.49
HPGD P15428 1/20 0.49
ALOX15 P16050 1/20 0.49
ABHD6 Q9BV23 2/20 0.46
POLB P06746 2/20 0.45
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 2/20 0.44
HTT P42858 1/20 0.44
LMNA P02545 3/20 0.44
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19607576 1.00 LIPA (1.00) LIPAALDH1A1MAPTHSD17B10KDM4E
SCHEMBL17078253 1.00 LIPA (1.00) LIPAALDH1A1MAPTHSD17B10KDM4E
SCHEMBL17078300 0.90 LIPA (1.00) LIPAALDH1A1MAPTHSD17B10KDM4E
SCHEMBL17078235 0.90 LIPA (1.00) LIPAALDH1A1MAPTHSD17B10KDM4E
SCHEMBL19607575 0.90 LIPA (1.00) LIPAALDH1A1MAPTHSD17B10KDM4E
SCHEMBL17078227 0.88 LIPA (1.00) LIPAALDH1A1MAPTHSD17B10KDM4E
SCHEMBL19584717 0.85 LIPA (0.72) LIPAALDH1A1MAPTHSD17B10KDM4E
SCHEMBL17078250 0.82 LIPA (1.00) LIPAALDH1A1MAPTHSD17B10KDM4E
SCHEMBL11150108 0.69 ALDH1A1 (0.53) LIPAALDH1A1MAPTHSD17B10POLB
SCHEMBL19584750 0.66 LIPA (0.49) LIPAALDH1A1MAPTHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015135652-A1 ANTAGONISTS OF ACID LIPASE FOR PREVENTING VIRUS INFECTION Technische Universität München (DE) 2015-09-17 WO claimed
WO-2026089560-A1 NOVEL NEAR-INFRARED PHOSPHOR COMPOUND AND USES THEREOF 서울대학교산학협력단 2026-04-30 WO disclosed
US-20250177341-A1 DIETARY TRIPROPIONIN SUPPLEMENTATION TO REDUCE ADIPOSITY AND IMPROVE GLUCOSE HOMEOSTASIS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2025-06-05 US disclosed
US-20250114313-A1 OLIGO-BENZAMIDE ANALOGS AND THEIR USE IN CANCER TREATMENT BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-04-10 US disclosed
WO-2024197271-A1 TARGETING LYSOSOMAL LIPID IN ALZHEIMER'S DISEASE THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2024-09-26 WO disclosed
US-20240299483-A1 TARGETS AND BIOMARKERS FOR TUMOR MICROENVIRONMENTS THE TRUSTEES OF INDIANA UNIVERSITY 2024-09-12 US disclosed
US-20240115735-A1 MATERIALS AND METHODS FOR THE TREATMENT OF LYSOSOMAL ACID LIPASE DEFICIENCY (LAL-D) RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL 2024-04-11 US disclosed
US-20240067942-A1 LYSOSOMAL ACID LIPASE VARIANTS AND USES THEREOF Universite Paris-Saclay (FR) 2024-02-29 US disclosed
EP-4284413-A1 MATERIALS AND METHODS FOR THE TREATMENT OF LYSOSOMAL ACID LIPASE DEFICIENCY (LAL-D) Research Institute at Nationwide Children's Hospital (US) 2023-12-06 EP disclosed
CN-116917471-A Lysosomal acid lipase variants and uses thereof 吉尼松公司 2023-10-20 CN disclosed
WO-2022164860-A1 MATERIALS AND METHODS FOR THE TREATMENT OF LYSOSOMAL ACID LIPASE DEFICIENCY (LAL-D) RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) 2022-08-04 WO disclosed
US-11396499-B2 Lysosomal acid lipase assay UNIVERSITY OF WASHINGTON (US) 2022-07-26 US disclosed
US-20220228152-A1 OLIGONUCLEOTIDE THERAPY FOR WOLMAN DISEASE AND CHOLESTERYL ESTER STORAGE DISEASE DEEP GENOMICS INCORPORATED (CA) 2022-07-21 US disclosed
US-20220226339-A1 INHIBITATION OF ACID LIPASE FOR CANCER THERAPY HEINRICH-HEINE-UNIVERSITÄT DÜSSELDORF (DE) 2022-07-21 US disclosed
WO-2022122883-A1 LYSOSOMAL ACID LIPASE VARIANTS AND USES THEREOF GENETHON (FR) 2022-06-16 WO disclosed
EP-3994276-A1 INHIBITATION OF ACID LIPASE FOR CANCER THERAPY Heinrich-Heine-Universität Düsseldorf (DE) 2022-05-11 EP disclosed
WO-2022081567-A1 METHODS FOR REVERSING HEPATIC STEATOSIS BRIGHTSEED, INC. (US) 2022-04-21 WO disclosed
EP-3976788-A1 OLIGONUCLEOTIDE THERAPY FOR WOLMAN DISEASE AND CHOLESTERYL ESTER STORAGE DISEASE Deep Genomics Incorporated (CA) 2022-04-06 EP disclosed
WO-2017194734-A1 MEANS AND METHODS FOR TREATING MYCOBACTERIAL DISEASES Technische Universität München (DE) 2017-11-16 WO disclosed
WO-2015135652-A1 ANTAGONISTS OF ACID LIPASE FOR PREVENTING VIRUS INFECTION Technische Universität München (DE) 2015-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250114313-A1 OLIGO-BENZAMIDE ANALOGS AND THEIR USE IN CANCER TREATMENT GAA, LIPA, LIPE LIPA 2/4885ALDH1A1 2879/4885MAPT 2687/4885
US-20250177341-A1 DIETARY TRIPROPIONIN SUPPLEMENTATION TO REDUCE ADIPOSITY AND IMPROVE GLUCOSE HOMEOSTASIS GPR119, FABP4, MTPN LIPA 1968/4885ALDH1A1 2876/4885MAPT 3849/4885
US-11396499-B2 Lysosomal acid lipase assay LIPA, LPL, PNLIP LIPA 1/4885ALDH1A1 1095/4885MAPT 3944/4885
US-20220226339-A1 INHIBITATION OF ACID LIPASE FOR CANCER THERAPY PNLIP, LPL, LIPA LIPA 3/4885ALDH1A1 194/4885MAPT 4731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.